Anti-CD19 immunotherapy - Eureka Therapeutics

Drug Profile

Anti-CD19 immunotherapy - Eureka Therapeutics

Alternative Names: CD19(7)-ARTEMISTM T cell therapy

Latest Information Update: 15 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eureka Therapeutics
  • Class Antibodies; CAR-T cell therapies; Cell therapies
  • Mechanism of Action CD19 antigen modulators; Cytotoxic T lymphocyte stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 03 Dec 2016 Preclinical trials in Haematological malignancies in USA (IV)
  • 03 Dec 2016 Eureka Therapeutics plans a phase I trial for Haematological malignancies
  • 03 Dec 2016 Pharmacodynamics data from a preclinical study in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top